Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
An interactive graphic provides details about six drugs currently being tested in the fight against ALS
Posted on Wednesday, May 1, 2013 - 09:30, By: Amy Madsen
Research seeking therapies for ALS is advancing at a rapid pace, and there are more potential treatments in clinical trials than ever before. Here, we look at six drugs currently in clinical trials for ALS: arimoclomol, Gilenya, ozanezumab, pyrimethamine, rasagiline and tirasemtiv.
How to use the...
Posted on Wednesday, May 1, 2013 - 09:23, By: Amy Madsen
Update (Aug. 26, 2013): This trial is recruiting participants at its Boston, Mass., trial site.
ALS TDI’s phase 2a clinical trial will assess the safety and tolerability of an approved multiple sclerosis drug, Gilenya, in people with amyotrophic lateral sclerosis
Posted on Monday, February 11, 2013 - 06:12, By: Amy Madsen
Update (Aug. 26, 2013): This trial is recruiting participants at its Boston trial site. For updates about the trial’s other sites, see Gilenya in Amyotrophic Lateral Sclerosis, or search for trial ID NCT01786174 at ClinicalTrials.gov.
A webinar hosted by ALS TDI reviews the biotech's development of TDI 132 (Gilenya), a drug that modulates the immune system
Posted on Friday, March 23, 2012 - 12:51, By: Amy Madsen
An overview of the development of TDI 132 for use in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) was the topic of a webinar hosted March 12, 2012, by the nonprofit biotech ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass.
The MDA-supported ALS Therapy Development Institute plans to launch a phase 2 clinical trial of TDI 132, a compound that modulates the immune system
Posted on Tuesday, February 14, 2012 - 11:30, By: Amy Madsen
A phase 2 clinical trial is set to begin of TDI 132, a compound that modulates the immune system, the ALS Therapy Development Institute (ALS TDI) announced today.
TDI 132, also known as fingolimod (brand name Gilenya), already is approved by the U.S. Food and Drug Administration (FDA) for the...